These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37652236)

  • 1. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
    Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
    Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
    Sousa S; Auriola S; Mönkkönen J; Määttä J
    BMC Cancer; 2015 Jan; 15():4. PubMed ID: 25588705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
    Petruk N; Siddiqui A; Tadayon S; Määttä J; Mattila PK; Jukkola A; Sandholm J; Selander KS
    Front Immunol; 2023; 14():1179022. PubMed ID: 37533856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
    Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
    Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
    Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
    J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT; Holen I; Dear TN; Hunter K; Brown HK
    Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
    Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
    J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.
    Sabatino R; Battistelli S; Magnani M; Rossi L
    Drug Deliv Transl Res; 2018 Oct; 8(5):1355-1364. PubMed ID: 30014237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
    Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
    Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
    Shoji R; Tsuchie H; Nagasawa H; Hongo M; Kasukawa Y; Nozaka K; Kudo D; Saito H; Abe K; Igarashi S; Harata S; Kasama F; Miyakoshi N
    Anticancer Res; 2022 Nov; 42(11):5357-5363. PubMed ID: 36288846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
    Hung TT; Chan J; Russell PJ; Power CA
    PLoS One; 2011; 6(5):e19389. PubMed ID: 21603655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
    Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
    Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
    Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
    Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
    Liu B; Yang Q; Cheng Y; Liu M; Ji Q; Zhang B; Yang Z; Zhou S; Liu D
    Acta Biomater; 2023 Aug; 166():640-654. PubMed ID: 37236576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
    Espinoza I; Liu H; Busby R; Lupu R
    Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
    Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
    J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.